EP1590442A4 - Inhibiteurs macrocycliques de la serine protease de l'hepatite c - Google Patents

Inhibiteurs macrocycliques de la serine protease de l'hepatite c

Info

Publication number
EP1590442A4
EP1590442A4 EP04709020A EP04709020A EP1590442A4 EP 1590442 A4 EP1590442 A4 EP 1590442A4 EP 04709020 A EP04709020 A EP 04709020A EP 04709020 A EP04709020 A EP 04709020A EP 1590442 A4 EP1590442 A4 EP 1590442A4
Authority
EP
European Patent Office
Prior art keywords
protease inhibitors
serine protease
macrocyclic hepatitis
macrocyclic
hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04709020A
Other languages
German (de)
English (en)
Other versions
EP1590442A3 (fr
EP1590442A2 (fr
Inventor
Zenwei Miao
Ying Sun
Frank Wu
Suanne Nakajima
Guoyou Xu
Yat Sun Or
Zhe Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enanta Pharmaceuticals Inc
Original Assignee
Enanta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/384,120 external-priority patent/US20040180815A1/en
Application filed by Enanta Pharmaceuticals Inc filed Critical Enanta Pharmaceuticals Inc
Publication of EP1590442A2 publication Critical patent/EP1590442A2/fr
Publication of EP1590442A3 publication Critical patent/EP1590442A3/fr
Publication of EP1590442A4 publication Critical patent/EP1590442A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
EP04709020A 2003-02-07 2004-02-06 Inhibiteurs macrocycliques de la serine protease de l'hepatite c Withdrawn EP1590442A4 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US36094703A 2003-02-07 2003-02-07
US360947 2003-02-07
US36585403A 2003-02-13 2003-02-13
US365854 2003-02-13
US10/384,120 US20040180815A1 (en) 2003-03-07 2003-03-07 Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
US384120 2003-03-07
PCT/US2004/003479 WO2004072243A2 (fr) 2003-02-07 2004-02-06 Inhibiteurs macrocycliques de la serine protease de l'hepatite c

Publications (3)

Publication Number Publication Date
EP1590442A2 EP1590442A2 (fr) 2005-11-02
EP1590442A3 EP1590442A3 (fr) 2005-11-03
EP1590442A4 true EP1590442A4 (fr) 2007-07-18

Family

ID=32872697

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04709020A Withdrawn EP1590442A4 (fr) 2003-02-07 2004-02-06 Inhibiteurs macrocycliques de la serine protease de l'hepatite c

Country Status (7)

Country Link
EP (1) EP1590442A4 (fr)
JP (1) JP2007524576A (fr)
KR (1) KR100940619B1 (fr)
CN (1) CN1771050A (fr)
AU (1) AU2004211637C1 (fr)
CA (1) CA2515216A1 (fr)
WO (1) WO2004072243A2 (fr)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9712544B1 (pt) 1996-10-18 2013-10-22 Inibidores de proteases de serina, composição farmacêutica compreendendo os mesmos e seus usos
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US7601709B2 (en) 2003-02-07 2009-10-13 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
US7176208B2 (en) 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
US7273851B2 (en) 2003-06-05 2007-09-25 Enanta Pharmaceuticals, Inc. Tri-peptide hepatitis C serine protease inhibitors
WO2004113365A2 (fr) * 2003-06-05 2004-12-29 Enanta Pharmaceuticals, Inc. Inhibiteurs de la tripeptide hepatite c serine protease
US7125845B2 (en) 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
JP4525982B2 (ja) 2003-09-26 2010-08-18 シェーリング コーポレイション Ｃ型肝炎ウイルスのｎｓ３セリンプロテアーゼの大環状インヒビター
KR20060130027A (ko) 2003-10-10 2006-12-18 버텍스 파마슈티칼스 인코포레이티드 세린 프로테아제, 특히 ｈｃｖ ｎｓ3-ｎｓ4ａ 프로테아제의억제제
AR048401A1 (es) 2004-01-30 2006-04-26 Medivir Ab Inhibidores de la serina-proteasa ns3 del vhc
AU2005212257A1 (en) 2004-02-04 2005-08-25 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
EP1718608B1 (fr) 2004-02-20 2013-07-17 Boehringer Ingelheim International GmbH Inhibiteurs de la polymerase virale
JP5425398B2 (ja) * 2004-12-22 2014-02-26 アンブレツクス・インコーポレイテツド 非天然アミノ酸及びポリペプチドを含む組成物、非天然アミノ酸及びポリペプチドに関連する方法並び非天然アミノ酸及びポリペプチドその使用
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2006096652A2 (fr) * 2005-03-08 2006-09-14 Boehringer Ingelheim International Gmbh Preparation de composes macrocycliques
US7592336B2 (en) 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7601686B2 (en) 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7470664B2 (en) * 2005-07-20 2008-12-30 Merck & Co., Inc. HCV NS3 protease inhibitors
EP2305695A3 (fr) 2005-07-25 2011-07-27 Intermune, Inc. Inhibiteurs macrocycliques de la multiplication du virus de L'Hépatite C
CN101273030B (zh) 2005-07-29 2012-07-18 泰博特克药品有限公司 丙型肝炎病毒的大环抑制剂
EP1913015B1 (fr) * 2005-07-29 2013-12-11 Janssen R&D Ireland Inhibiteurs macrocycliques du virus de l'hépatite c
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
TWI382025B (zh) 2005-07-29 2013-01-11 Tibotec Pharm Ltd Ｃ型肝炎病毒之大環抑制劑（四）
PE20070343A1 (es) * 2005-07-29 2007-05-12 Medivir Ab Inhibidores macrociclicos del virus de la hepatitis c
JP5230417B2 (ja) 2005-07-29 2013-07-10 テイボテク・フアーマシユーチカルズ Ｃ型肝炎ウイルスの大員環インヒビター
DK1919898T3 (da) 2005-07-29 2011-05-02 Tibotec Pharm Ltd Makrocykliske inhibitorer af hepatitis-C-virus
TWI383980B (zh) 2005-07-29 2013-02-01 Tibotec Pharm Ltd Ｃ型肝炎病毒之大環抑制劑
NZ565540A (en) 2005-08-02 2011-06-30 Vertex Pharma Inhibitors of serine proteases
JP5015154B2 (ja) 2005-08-12 2012-08-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウイルスポリメラーゼインヒビター
EP2364970A1 (fr) 2005-08-19 2011-09-14 Vertex Pharmaceuticals Incorporated Procédés et intermédiaires
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
BRPI0617274A2 (pt) 2005-10-11 2011-07-19 Intermune Inc compostos e métodos para a inibição de replicação viral de hepatite c
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP1951748B1 (fr) 2005-11-11 2013-07-24 Vertex Pharmaceuticals, Inc. Variantes du virus de l'hépatite c
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US9526769B2 (en) 2006-06-06 2016-12-27 Enanta Pharmaceuticals, Inc. Macrocylic oximyl hepatitis C protease inhibitors
US20070281884A1 (en) * 2006-06-06 2007-12-06 Ying Sun Macrocyclic oximyl hepatitis C protease inhibitors
US8268776B2 (en) 2006-06-06 2012-09-18 Enanta Pharmaceuticals, Inc. Macrocylic oximyl hepatitis C protease inhibitors
UY30437A1 (es) * 2006-06-26 2008-01-31 Enanta Pharm Inc Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c
RU2008152171A (ru) 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
EP2038275B1 (fr) * 2006-07-07 2010-01-06 Gilead Sciences, Inc. Nouveau composé à base de pyrizadine et son utilisation
UA96296C2 (en) * 2006-07-07 2011-10-25 Гилиад Сайенсиз, Инк. Pyridazine compounds and use thereof
EP2049474B1 (fr) 2006-07-11 2015-11-04 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
WO2008008502A1 (fr) 2006-07-13 2008-01-17 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptides en tant qu'inhibiteurs de la réplication virale
WO2008019303A2 (fr) * 2006-08-04 2008-02-14 Enanta Pharmaceuticals, Inc. Inhibiteurs de sérine protéases de l'hépatite c macrocycliques de type pyridazinonyle
US7718612B2 (en) * 2007-08-02 2010-05-18 Enanta Pharmaceuticals, Inc. Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
AU2007284027A1 (en) 2006-08-17 2008-02-21 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2008205116A1 (en) * 2007-01-08 2008-07-17 Phenomix Corporation Macrocyclic hepatitis C protease inhibitors
CL2008000321A1 (es) * 2007-02-01 2008-08-22 Tibotec Pharm Ltd Compuesto macrociclo en forma cristalina, inhibidor del virus de la hepatitis c (vhc); mezcla de una o mas formas cristalinas; procesos de preparacion de las formas cristalinas; y composicion farmaceutica que las comprende.
EP2495249A1 (fr) 2007-02-26 2012-09-05 Achillion Pharmaceuticals, Inc. Peptides à amine tertiaire substituée utiles en tant qu'inhibiteurs de la réplication du VHC
ES2381410T3 (es) 2007-05-04 2012-05-28 Vertex Pharmceuticals Incorporated Terapia de combinación paa el tratamiento de infecciones por VHC
CA2692145C (fr) 2007-06-29 2015-03-03 Gilead Sciences, Inc. Composes antiviraux
AP2874A (en) 2007-06-29 2014-03-31 Gilead Sciences Inc Antiviral compounds
EP2188274A4 (fr) 2007-08-03 2011-05-25 Boehringer Ingelheim Int Inhibiteurs de polymerase virale
US8383583B2 (en) 2007-10-26 2013-02-26 Enanta Pharmaceuticals, Inc. Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
US8263549B2 (en) 2007-11-29 2012-09-11 Enanta Pharmaceuticals, Inc. C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors
WO2009070689A1 (fr) 2007-11-29 2009-06-04 Enanta Pharmaceuticals, Inc. Dérivés de proline bicycliques substitués en c5 en tant qu'inhibiteurs de la protéase ns3 du virus de l'hépatite c
JP5529036B2 (ja) 2007-12-05 2014-06-25 エナンタ ファーマシューティカルズ インコーポレイテッド フッ素化トリペプチドｈｃｖセリンプロテアーゼ阻害剤
CN101903351B (zh) 2007-12-19 2014-09-10 贝林格尔.英格海姆国际有限公司 病毒聚合酶抑制剂
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
ES2437147T3 (es) * 2008-02-04 2014-01-09 Idenix Pharmaceuticals, Inc. Inhibidores de serina proteasa macrocíclicos
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2009148923A1 (fr) 2008-05-29 2009-12-10 Bristol-Myers Squibb Company Inhibiteurs du virus de l’hépatite c
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) * 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2010068761A2 (fr) * 2008-12-10 2010-06-17 Achillion Pharmaceuticals, Inc. Analogues cycliques de peptides a-amino-4-oxobutanoyl, inhibiteurs de la réplication virale
PT2364309E (pt) 2008-12-10 2015-01-14 Achillion Pharmaceuticals Inc Novos péptidos 4-amino-4-oxobutanoil como inibidores de replicação viral
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2385838A1 (fr) 2009-01-07 2011-11-16 Scynexis, Inc. Dérivé de cyclosporine convenant au traitement de l'infection par vhc et vih
TW201040181A (en) 2009-04-08 2010-11-16 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
US8936781B2 (en) 2009-05-13 2015-01-20 Enanta Pharmaceuticals, Inc. Macrocyclic compounds as hepatitis C virus inhibitors
WO2011017389A1 (fr) 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Inhibiteurs macrocycliques de la sérine protéase macrocyclique utiles contre les infections virales, en particulier le virus de l’hépatite c
LT2477980T (lt) 2009-09-15 2016-09-26 Taigen Biotechnology Co., Ltd. Hcv proteazės slopikliai
CA2801584A1 (fr) * 2010-06-07 2011-12-15 Abbvie Inc. Inhibiteurs macrocyclique de la protease a serine du virus de l'hepatite c
HUE028384T2 (en) 2010-09-21 2016-12-28 Enanta Pharm Inc HCV serine protease inhibitors derived from macrocyclic proline
EP2658858A4 (fr) 2010-12-30 2014-06-25 Enanta Pharm Inc Inhibiteurs macrocycliques de phénanthridine de sérine protéase d'hépatite c
WO2012092409A2 (fr) 2010-12-30 2012-07-05 Enanta Phararmaceuticals, Inc Inhibiteurs macrocycliques de sérine protéase d'hépatite c
WO2012109398A1 (fr) 2011-02-10 2012-08-16 Idenix Pharmaceuticals, Inc. Inhibiteurs macrocycliques de sérine protéase, compositions pharmaceutiques les contenant et leur utilisation pour le traitement des infections par le vhc
US8957203B2 (en) * 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PT2909205T (pt) * 2012-10-19 2017-02-06 Bristol Myers Squibb Co Derivados de carbamato de hexadecahidrociclopropa(e)pirrolo(1,2- a)(1,4)diazaciclopentadecinilo substituídos com 9-metilo como inibidores da protease não estrutural 3 (ns3) para o tratamento de infeções por vírus da hepatite c
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP6342922B2 (ja) 2013-03-07 2018-06-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
CA2905433A1 (fr) 2013-03-14 2014-09-25 Achillion Pharmaceuticals, Inc. Processus innovants de production de sovaprevir
WO2014145600A1 (fr) 2013-03-15 2014-09-18 Achillion Pharmaceuticals, Inc. Polymorphes de sel de sodium d'ach-0142684, composition les comprenant, et leur procédé de fabrication
MX2015013020A (es) 2013-03-15 2016-06-10 Achillion Pharmaceuticals Inc Polimorfos de sovaprevir y metodos de fabricacion de los mismos.
US9006423B2 (en) 2013-03-15 2015-04-14 Achillion Pharmaceuticals Inc. Process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
WO2015103490A1 (fr) 2014-01-03 2015-07-09 Abbvie, Inc. Formes galéniques antivirales solides
EP2899207A1 (fr) 2014-01-28 2015-07-29 Amikana.Biologics Nouveau procédé pour tester l'inhibition de la protéase du HCV
CN105130916B (zh) * 2015-09-30 2019-03-01 江西师范大学 一种高效制备nh-1,2,3三唑化合物的方法
AR116978A1 (es) 2018-11-06 2021-06-30 Fmc Corp Fungicidas de tolilo sustituido
WO2021127273A1 (fr) * 2019-12-20 2021-06-24 Gb004, Inc. Dérivés de 1-((6-oxo-1,6-dihydropyridazin-4-yl)méthyl)pipérazine et de 1-((6-oxo-1,6-dihydropyrimidin-4-yl)méthyl)pipérazine utilisés en tant que modulateurs de la prolyl hydroxylase, de l'hif-1 alpha et de la pgk dans le traitement de maladies inflammatoires, du cancer ou d'infections
UY39189A (es) 2020-05-06 2021-12-31 Fmc Corp Fungicidas de tolilo sustituido y sus mezclas

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000059929A1 (fr) * 1999-04-06 2000-10-12 Boehringer Ingelheim (Canada) Ltd. Peptides macrocycliques actifs contre le virus de l'hepatite c

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867185B2 (en) * 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000059929A1 (fr) * 1999-04-06 2000-10-12 Boehringer Ingelheim (Canada) Ltd. Peptides macrocycliques actifs contre le virus de l'hepatite c

Also Published As

Publication number Publication date
CA2515216A1 (fr) 2004-08-26
CN1771050A (zh) 2006-05-10
KR100940619B1 (ko) 2010-02-05
AU2004211637A1 (en) 2004-08-26
WO2004072243A2 (fr) 2004-08-26
WO2004072243A3 (fr) 2005-11-03
JP2007524576A (ja) 2007-08-30
KR20050111585A (ko) 2005-11-25
EP1590442A2 (fr) 2005-11-02
AU2004211637C1 (en) 2010-08-19
AU2004211637B2 (en) 2009-08-13

Similar Documents

Publication Publication Date Title
EP1590442A4 (fr) Inhibiteurs macrocycliques de la serine protease de l'hepatite c
EP1590442A3 (fr) Inhibiteurs macrocycliques de la serine protease de l'hepatite c
TWI367211B (en) Hcv ns-3 serine protease inhibitors
IL174459A0 (en) Macrocyclic inhibitors of hepatitis c virus ns3 serine protease
HK1090644A1 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
HK1098164A1 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
HK1095594A1 (en) 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives as inhibitors of serine proteases, particularly hcv ns3-ns4a protease
HK1081196A1 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
IL182339A0 (en) Hcv ns3-ns4a protease inhibition
IL179844A0 (en) Five-membered heterocycles useful as serine protease inhibitors
EP1663281A4 (fr) Inhibiteurs de protease poly-pegylee
EP1499336A4 (fr) Inhibiteurs de protease
EP1694647A4 (fr) Inhibiteurs des proteases a cysteine du type cathepsine
EP1673336A4 (fr) Inhibiteurs de cathepsine et de cysteine protease
AU2003277891A1 (en) Hcv ns-3 serine protease inhibitors
EP1663279A4 (fr) Inhibiteurs de protease modifies
EP1704142A4 (fr) Inhibiteurs de la protease
EP1594505A4 (fr) Derives de phenylglycine utiles en tant qu'inhibiteurs de serine protease
AU2003269984A8 (en) Protease inhibitors
EP1706402A4 (fr) Inhibiteurs des cysteines proteases de type cathepsine
IL173953A0 (en) Plasminogen activators
ZA200610586B (en) Five-membered heterocycles useful as serine protease inhibitors
EP1715920A4 (fr) Inhibiteurs de cathepsine cysteine protease
AU2003292406A8 (en) Serine protease
AU2003263738A8 (en) Protease inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050805

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 38/05 A

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1082768

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20070614

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 31/14 20060101ALI20070608BHEP

Ipc: C07D 513/04 20060101ALI20070608BHEP

Ipc: C07D 487/04 20060101ALI20070608BHEP

Ipc: A61K 38/05 20060101AFI20051108BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20100818

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1082768

Country of ref document: HK